RZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Launches Investigation into Rezolute

Core Viewpoint - Faruqi & Faruqi, LLP has initiated an investigation into Rezolute, Inc. following a significant drop in its stock price due to disappointing results from a clinical trial for its lead drug candidate, ersodetug [1]. Group 1: Company Overview - Rezolute, Inc. is a biopharmaceutical company focused on developing treatments for congenital hyperinsulinism [1]. - The company's lead drug candidate, ersodetug, was undergoing a Phase 3 clinical trial [1]. Group 2: Clinical Trial Results - The Phase 3 sunRIZE clinical trial for ersodetug failed to meet both its primary and key secondary endpoints [1]. - The highest dose in the trial showed reductions in hypoglycemia events that were not statistically significant compared to placebo [1]. Group 3: Stock Performance - On December 11, 2025, Rezolute's shares plummeted from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% decline [1]. - Trading was halted under Nasdaq's volatility controls due to the drastic drop in stock price [1].